Phase
Condition
Allergy
Urticaria
Hives (Urticaria)
Treatment
Placebo
OCTA-C1-INH
Clinical Study ID
Ages > 2 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Is at least 18 years of age (applicable for 1st study phase) or is at least 2 yearsof age (applicable for 2nd study phase)
Has confirmed diagnosis of HAE type I or II
Has had at least 3 moderate or severe HAE attacks (excluding extremity attacks) inthe last 3 months before the Screening Visit. For participants ≥2 and ≤12 years ofage, has had at least 1 moderate or severe HAE attack (excluding extremity attacks)in the last 6 months before Screening Visit
Has a documented congenital C1-INH functional activity <50% with or without C1-INHdeficiency and C4 antigen level below the laboratory reference range
Participant or the participant's legally authorized representative(s) has signedinformed consent (as required by local law), with the assent of participants legallycapable of providing it, as applicable
States willingness to comply with all study procedures and availability for theduration of the study
If the participant is of childbearing potential (CBP), has a negative pregnancy testand must have been using a highly effective method of contraception and continue todo so until at least 2 weeks after their last dose (for both blinded and open-labeldoses of IMP). Not of CBP is defined as surgically sterilized (hysterectomy,bilateral oophorectomy) or who are postmenopausal (defined as women with no mensesfor 12 months without an alternative medical cause). Highly effective methods ofcontraception:
Combined hormonal contraception (estrogens and progesterone) methods such asoral, implantable, intravaginal, injectable, or transdermal contraceptives at astable dose for a minimum of 1 full cycle (hormonal contraceptives must inhibitovulation) and for at least 4 weeks before screening
Progesterone only hormonal contraception associated with inhibition ofovulation (oral, injectable, implantable)
Intrauterine device
Intrauterine hormone-releasing system inserted at least 4 weeks beforescreening
Bilateral tubal ligation/occlusion or vasectomized partner (with surgicalsuccess confirmed by medical assessment) OR Agrees to abstain from heterosexualintercourse during study participation and to use a highly effectivecontraceptive (as described above) as backup if they become sexually activeduring the study. Abstinence is only acceptable if this is the participant'susual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulationmethods), withdrawal (coitus interruptus), spermicides only, and lactationalamenorrhea method are not acceptable methods of contraception
Note: If a participant of CBP has a positive or suspected positive urinepregnancy test within 72 hours prior to treatment, a serum pregnancy test willbe required
Male participants must not plan to father a child or donate sperm for 90 daysafter their last dose of study drug (for both blinded and open-label doses ofthe IMP). However, there are no official contraception requirements for maleparticipants during the study.
Inclusion Criteria for IMP Dosing for QAT:
Has confirmed QAT per definition criteria
Has a swelling episode that is new and not the continuation of a previous HAE attack
Exclusion
Exclusion Criteria:
Has a history of clinically relevant antibody development against C1-INH
Has a medical history consistent with Type 3 HAE (i.e., onset at age above 40 year,no family history, no known HAE mutation, low C1q level in plasma)
Has a history of allergic reaction to C1-INH or other blood/plasma product
Has a history of B-cell malignancy that was unresolved in the past 5 years
Has a narcotic and/or alcoholic addiction
Has participated in any other investigational drug evaluation within 30 days beforescreening
Is pregnant or breastfeeding
Has any clinically significant medical or psychiatric condition that, in theinvestigator's opinion would interfere with the participant's ability to participatein the study
Has a history of thromboembolic events (TEEs), myocardial infarction, unstableangina pectoris, critical aortic stenosis, cerebrovascular accident, transientischemic attack, severe peripheral vascular disease, or disseminated intravascularcoagulation within one year before screening
(applicable until IDMC review of the interim preliminary safety and efficacy data):has clinically significant derangement in measurements of cardiovascular status (i.e. uncontrolled arterial hypertension, cardiac insufficiency New York HeartAssociation (NYHA) class III-IV), pulmonary status (i.e., COPD GOLD classification 3and 4, severe asthma) and renal status (i.e., eGFR below 90 ml/min per 1.73 m2)
Exclusion Criteria for IMP Dosing for QAT:
Has received blood or a blood product for prophylactic or acute treatment with anyC1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykininand kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), ortreatment with tranexamic acid within 14 days before dosing with the IMP (or is notwilling to abstain from these medications throughout the study)
started or changed hormone replacement therapy or selective estrogen receptormodulators (e.g., tamoxifen) within 14 days before IMP dosing
Started or changed androgen therapy (e.g. testosterone, dehydro-epiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) within 14 daysbefore IMP dosing or is not willing to maintain a stable dose throughout the study
Started or changed the dose of monoclonal antibodies e.g. lanadelumab within 11weeks before dosing or not willing to maintain a stable dose throughout the study
Has used narcotic pain medications or non-opioid analgesics within 7 days before IMPdosing for a QAT
Has received OCTA-C1-INH within 14 days before IMP dosing
Exclusion Criteria for IMP Dosing for PK:
Has received blood or a blood product for prophylactic or acute treatment with anyC1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykininand kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), ortreatment with tranexamic acid within 14 days before dosing with the IMP (or is notwilling to abstain from these medications throughout the study)
Is receiving hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) and has had their dose changed within 14 days before IMP dosing
Is receiving or has received androgen therapy (e.g., testosterone,dehydroepiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) IN ANYDOSE within 14 days before dosing
Started or changed the dose of monoclonal antibodies e.g lanadelumab within 11 weeksbefore dosing or not willing to maintain a stable dose throughout the study
Has used narcotic pain medications or non-opioid analgesics within 7 days before IMPdosing
Has received IMP within 14 days before IMP dosing
Has planned dental, medical, or surgical procedures during the PK Period that willrequire pre-procedural prevention
Study Design
Connect with a study center
Octapharma Research Site
Yerevan,
ArmeniaActive - Recruiting
Octapharma Research Site
Sofia, 1431
BulgariaActive - Recruiting
Octapharma Research Site
Mexico City, 06720
MexicoSite Not Available
Octapharma Research Site
Podgorica,
MontenegroSite Not Available
Octapharma Research Site
Lima, 15001
PeruSite Not Available
Institutul Regional de Gastroenterologie si Hepatologie "Prof dr. Octavian Fodor" Cluj-Napoca
Cluj-Napoca, 400162
RomaniaActive - Recruiting
Octapharma Research Site
Cluj-Napoca, 400162
RomaniaActive - Recruiting
Octapharma Research Site
Belgrade, 11221
SerbiaSite Not Available
Octapharma Research Site
Kragujevac, 11221
SerbiaActive - Recruiting
Octapharma Research Site
Kyiv, 03057
UkraineActive - Recruiting
Octapharma Research Site
Lviv, 79010
UkraineActive - Recruiting
Octapharma Research Site
Centennial, Colorado 80112
United StatesActive - Recruiting
Octapharma Research Site
Farmington Hills, Michigan 48334
United StatesActive - Recruiting
Octapharma Research Site
Toledo, Ohio 43617
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.